Sanofi Diabetes: shaping the future of integrated diabetes care

People with diabetes are entitled to the best support to meet their needs. With innovation at its foundation, Sanofi has been shaping the future of diabetes care for more than 90 years. The company has an ongoing track record of generating and contributing knowledge to the global diabetes community in order to advance patient care and safeguard the health of people with diabetes.

Sanofi’s established heritage in innovation can be traced back to the production of insulin at the beginning of the 20th Century when, with the introduction of “Insulin Hoechst”, they were one of the first in Europe to provide industrially-produced insulin with a consistent standard of purity and quality on a large scale.1

Sanofi Diabetes is driving innovation focused on patient needs

From these early years, Sanofi has continued to innovate by improving production techniques and developing new treatments for patients and today, Sanofi has an international reputation of bringing innovation, education and support to patients at every level of their journey with diabetes.

This is achieved through a focus on discovery, research and development by in-house R&D teams and through working together with others at the leading edge of diabetes academic research, business development, and patient advocacy around the world.

Sanofi Diabetes HQ is co-located in Paris (France), Bridgewater (U.S.) and in Frankfurt (Germany), which is also the center for R&D in new diabetes therapies and medical devices. The company's extensive operational reach benefits from direct local contact in many countries around the world and includes manufacturing facilities, such as in Germany, Russia, China and India.

Shaping integrated diabetes care

The call to foresee the needs of people with diabetes and address the worldwide fragmentation of care intensifies every day. This is why, as a leader in integrated diabetes care, Sanofi Diabetes delivers solutions that directly target the different needs of people living with diabetes around the world, working together with partners in order to achieve personalized, outcome driven diabetes care in five core areas:-

- Finding easier insulin solutions to achieve target A1c and improve standards of care
- Addressing patient needs with innovation over and above glucose control
- Supporting healthcare systems with easier and newer ways to deliver care
- Actively driving and leading new initiatives in Public Health
- Reaching all populations in emerging countries with a tailored approach

Key points

- Sanofi’s focus in diabetes can be traced back to 1923 and the early years of insulin treatment.
- For over 90 years the company has continued to innovate by pioneering production techniques and new integrated solutions including therapies and medical devices.
- Today Sanofi has an international reputation of bringing innovation, education and support in diabetes care achieved by in-house R&D teams and through working together with other organizations at the leading edge of diabetes academic research, business development, and patient advocacy around the world.
Driving innovation at every level, the company’s R&D effort is continually focused on evolving its portfolio of therapies and devices to best serve patients’ needs.

By combining the latest research and development with the most up-to-date technology, Sanofi provides a comprehensive portfolio that goes beyond insulin to span a range of evidence-based therapies and user-centric devices, which includes design award-winning injection pens and blood glucose meters.

Through active research partnerships, the company is advancing scientific thinking in many aspects of diabetes care, from identifying therapeutic approaches and technological solutions that simplify and improve overall diabetes management to increasing understanding of diabetes in different patient populations to predict responses to treatment.

Sanofi is also pioneering solutions that are easily integrated into daily life, thereby helping many millions of people self-manage their condition.

In partnership with leaders in diabetes academic research, physician organizations and patient advocacy groups around the world, Sanofi is undertaking several large-scale research projects to increase understanding of patient needs and motivation, and using these insights to deliver programs of support to the entire diabetes community.

Comprehensive portfolio of integrated solutions throughout a patient’s journey with diabetes, for example:-

**Toujeo**® (insulin glargine [rDNA origin] injection, 300U/mL), a next-generation basal insulin for the treatment of type 1 and type 2 diabetes mellitus in adults. Toujeo® has been approved by the U.S. Food and Drug Administration (FDA), the European Commission and Health Canada, and is under review by other regulatory authorities around the world.2,3

**Afrezza**® (insulin human) Inhalation Powder, the only inhaled rapid-acting insulin, approved by the U.S. FDA and marketed only in the U.S. to control high blood sugar in adults with type 1 and type 2 diabetes.4

**Lyxumia**® (lixisenatide) is a once-daily prandial glucagon-like peptide-1 receptor agonist (GLP-1 RA) for the treatment of adult patients with type 2 diabetes mellitus. Recent top-line results of the Phase IIIb ELIXA cardiovascular outcomes study showed that lixisenatide was non-inferior, although not superior, to placebo for cardiovascular safety.5

**Lantus**® (insulin glargine [rDNA origin] injection, 100U/mL). Over 150 countries worldwide have access to Lantus®, the most studied basal insulin with more than 15 years’ proven efficacy and established safety,6-11 for the treatment of type 1 and type 2 diabetes.

**MyStar Connect**® supports healthcare professionals in the delivery of individualized patient care by providing necessary insights and analysis to optimize diabetes management. The new software is part of the **MyStar® portfolio** consisting of medical devices, support services and guidance and connects to Sanofi’s **BGStar®** and **MyStar Extra®** blood glucose meters.

In India, the high quality **AIISTAR™** reusable pen that can be used with Sanofi Diabetes insulin portfolio, was recently launched and demonstrates how Sanofi is making affordable and reliable delivery systems accessible to people living with diabetes in emerging countries.

Advancing knowledge to identify therapeutic approaches, technological solutions and increase understanding of patient needs, for example:-

**ELIXA (completed):** Cardiovascular outcome study for patients with type 2 diabetes after Acute Coronary Syndrome during treatment with Lyxumia® (lixisenatide).

**EDITION (completed):** Evaluating Toujeo® (insulin glargine [rDNA origin] injection, 300U/mL) versus Lantus® (insulin glargine [rDNA origin] injection, 100U/mL) for the treatment of diabetes in adults.

**The Real Life Study program (planned):** Comprises the ACHIEVE CONTROL, REACH CONTROL and REGAIN CONTROL studies and will compare the clinical effectiveness of Toujeo® with other basal insulins in people with type 2 diabetes, in a standard care setting, along with additional measures relating to patient experience and health resource utilization.

**GETGOAL DUO 2 (completed):** Comparing Lyxumia® (lixisenatide) versus insulin glulisine in terms of HbA1c reduction and body weight change at week 26 in patients with type 2 diabetes not adequately controlled on insulin glargine +/- metformin.

**INTENSE (ongoing):** (Intensifying Insulin Therapy in type 2 diabetes: lixisENatide or Standard of carE): A patient-centric non-interventional study of Lyxumia® (lixisenatide) to assess the safety and efficacy of adding injectable therapies to basal insulin, as well as the factors predicting the effectiveness of this intensification of treatment in a real-world setting.
**TEENs (ongoing):** Largest, contemporary real-life study assessing type 1 diabetes management and psychosocial parameters in nearly 6,000 youths aged 8–25 years from 5 continents, 20 countries and more than 200 centers worldwide. Through these investigations, TEENs provides a unique opportunity to set the foundation to drive recommendations for enhancing care and patient outcomes through interventions on modifiable factors.12

**IDMPS (ongoing):** The International Diabetes Management Practices Study is the world’s largest ongoing observational survey to assess changes in diabetes practices including management of care and resources used in education. Since 2005 more than 70,000 patients with type 1 and type 2 diabetes and 5,000+ doctors have taken part. The findings shed light on many aspects of diabetes practices.13

**Co-creating programs to bring better care for more people living with diabetes**

**Partners in Patient Health (PIPH) initiative:** Sanofi launched PIPH to support patients in becoming more empowered in their own care. Including live events and a digital tool, the initiative enables advocates and patient groups to connect across geographies to help each other improve their capacities to support diabetes and chronic disease.

**Rainbow Across Borders (RAB):** Sanofi joined with RAB with the aim of improving the quality of life of, and give dignity to, patients and their families challenged by chronic or life-threatening illnesses. RAB promotes regional collaboration and networking among patient organizations. The Sanofi-Rainbow Across Borders Asia Pacific Award is the first award of its kind in the region to recognize patient groups for their increasing role in helping and empowering patients.

**Be He@lthy, Be Mobile:** Mobile technology is increasingly being relied upon as an effective means of promoting better access to health information and services for communities everywhere. In February 2015, Sanofi joined ‘Be He@lthy, Be Mobile’ a concrete example of our commitment to providing better care for people with diabetes. Spearheaded by the World Health Organisation and the International Telecommunications Union, this international initiative exploits the widespread use of mobile applications and SMS messages to reinforce healthcare activities that prevent, treat and care for non-communicable diseases – including diabetes – in low and mid-income countries.

**Kids and Diabetes in Schools (KiDS):** In 2013, the International Diabetes Federation (IDF), in collaboration with the International Society for Paediatric and Adolescent Diabetes (ISPAD) and Sanofi Diabetes, launched the KiDS project in India and Brazil to raise awareness and improve prevention among school children. KiDS aims to foster a safe and supportive environment, one that creates a better understanding of diabetes, supports children with type 1 and type 2 diabetes and promotes the benefits of healthy nutrition and exercise habits at school. The first phase of the project was completed in India in 2014, involving more than 600 teachers from 15 schools (both government and private) in Delhi and reached approx. 300,000 students, teachers and families. In 2014, KiDS was also rolled out in Brazil and Canada, and will be implemented in other countries.

**Going beyond medicines to improve comprehensive diabetes management, treatment and care.**

- The impact of diabetes requires intervention at global and national policy level. Alongside the drive for cost control, policy makers are willing to invest to protect their populations from the consequences of diabetes.


- Sanofi is establishing partnerships with key stakeholders at the forefront of diabetes health and innovation to improve comprehensive diabetes management treatment and care.

[click here](http://www.epresspack.net/sanofi-diabetes-global-health) for Sanofi’s approach to diabetes global health

Sanofi Diabetes

---

**Sano**

**Fi Diabetes**

*Going beyond together*
Other educational and awareness programs worldwide include:

RUSSIA: The Shkola Diabeta website forms part of a wider program to provide support and educate diabetes patients, which include an annual sports event and a 24/7 free telephone hotline to provide easily-accessible advice.

MIDDLE EAST: My Diabetes Story is an online community which aims to enhance patient-to-patient communication. Those who join are invited to be a part of discussions, and build their own threads on their chosen topics.

FRENCH SPEAKING AFRICA: The e-diabete initiative provides a training program for health professionals to improve early diagnosis, reduce risks of complications and ensure delivery of improved care.

TURKEY: The Diabetes at School initiative covers 60,000 schools in partnership with the Turkish Ministries of Health and Education.

References:

1. Hoechst GmbH, company archive, Frankfurt. 75 Years of Insulin: 41.

*Not all products & programs are available in all countries*